Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 29.90
Bid: 29.10
Ask: 30.70
Change: 0.10 (0.34%)
Spread: 1.60 (5.498%)
Open: 29.80
High: 0.00
Low: 0.00
Prev. Close: 29.80
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - EKF Diagnostics Holdings Plc

23 Oct 2015 10:14

KILLIK & CO LLP - Form 8.3 - EKF Diagnostics Holdings Plc

KILLIK & CO LLP - Form 8.3 - EKF Diagnostics Holdings Plc

PR Newswire

London, October 23

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:Killik & Co
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeEKF Diagnostics Holdings Plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: No
(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure22/10/2015
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A” No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:
InterestsShort positions
Number%Number%
(1) Relevant securities owned and/or controlled:4,456,2051.06
(2) Cash-settled derivatives:
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:4,456,2051.06

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists: n/a
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchase/saleNumber of securitiesPrice per unit
Ord GBP0.01 Sale 28,571 GBP 0.20875

(b) Cash-settled derivative transactions

Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit

(ii) Exercise

Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”
None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?No

Date of disclosure:23/10/2015
Contact name:Julie Steele
Telephone number:020 7337 0400

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
22nd Apr 202411:53 amRNSPosting of Annual Report & Notice of AGM
25th Mar 20245:15 pmRNSDirector/PDMR Shareholding
20th Mar 20248:30 amRNSFinal Results
15th Mar 20247:00 amRNSInvestor Presentation – Revised start time
11th Mar 20247:00 amRNSNotice of Results and Investor Presentation
29th Jan 20247:00 amRNSTrading Update
11th Jan 20247:00 amRNSDirector/PDMR Shareholding
3rd Jan 20244:14 pmRNSHolding(s) in Company
29th Nov 20234:55 pmRNSHolding(s) in Company
26th Oct 20237:00 amRNSOpening of new US LS Manufacturing Facility
26th Sep 20237:00 amRNSInterim results
14th Sep 20237:00 amRNSNotice of Results & Investor Presentation
12th Sep 20237:01 amRNSTrading Update
12th Sep 20237:00 amRNSAppointment of CFO
26th Jul 20237:00 amRNSTrading Update
28th Jun 20237:00 amRNSDirectorate Change
20th Jun 20237:00 amRNSEnzyme fermentation capacity expansion progress
1st Jun 202311:07 amRNSHolding(s) in Company
24th May 20237:01 amRNSUpdate re. EKF distribution of shares in Verici Dx
24th May 20237:00 amRNSDistribution of shares in Verici Dx plc
22nd May 20232:52 pmRNSHolding(s) in Company
17th May 202311:50 amRNSResult of AGM and Voting Results
17th May 20237:00 amRNSAGM Statement
3rd May 20237:00 amRNSSuccessful quality management audits
25th Apr 20234:10 pmRNSTotal Voting Rights
21st Apr 20232:30 pmRNSPosting of Annual Report & Notice of AGM
28th Mar 20237:00 amRNSFinal Results
23rd Mar 20237:00 amRNSDisposal of ADL Health
1st Mar 20237:00 amRNSNotice of Results and Investor Presentation
21st Feb 20233:31 pmRNSHolding(s) in Company
10th Feb 20233:12 pmRNSHolding(s) in Company
6th Feb 20237:00 amRNSTrading update
9th Jan 20237:00 amRNSChange of Adviser
22nd Dec 20224:40 pmRNSSecond Price Monitoring Extn
22nd Dec 20224:35 pmRNSPrice Monitoring Extension
22nd Dec 20227:00 amRNSPoint-of-Care update
15th Dec 20224:52 pmRNSHolding(s) in Company
14th Dec 20224:32 pmRNSHolding(s) in Company
6th Dec 20225:30 pmRNSHolding(s) in Company
14th Nov 20225:52 pmRNSHolding(s) in Company
20th Sep 20227:01 amRNSDividend Timetable
20th Sep 20227:00 amRNSHalf-year Report
1st Sep 20227:00 amRNSNotice of Interim Results & Investor Presentation
1st Aug 20227:00 amRNSTrading Update
29th Jun 20224:41 pmRNSSecond Price Monitoring Extn
29th Jun 20224:36 pmRNSPrice Monitoring Extension
28th Jun 20223:34 pmRNSHolding(s) in Company
22nd Jun 20224:36 pmRNSPrice Monitoring Extension
21st Jun 20227:00 amRNSDirector/PDMR Shareholding
20th Jun 20227:00 amRNSDistribution of shares in Verici Dx plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.